RVNC's sell-off looks overdone; however, there will, IMO, be some delay—possibly material—in RVNC’s obtaining FDA approval in cervical dystonia due to slower than expected patient enrollment in the ASPEN-OLS (open-label safety) study.
The ASPEN-1 (CD efficacy) study probably won’t encounter a material delay insofar as all patients have been enrolled and injected (#msg-154265955).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.